参附注射液辅助GP方案对非小细胞肺癌患者T淋巴细胞亚群及血清血管内皮生长因子水平的影响研究

Impact of Shenfu Injection on T- lymphocyte Subsets and Serum VEGF Level of NSCLC Patients Treated by GP Chemotherapy Regimens

目的探究参附注射液辅助GP方案对非小细胞肺癌患者T淋巴细胞亚群及血清血管内皮生长因子(VEGF)水平的影响。方法选择2013年1月—2015年3月在常熟市第一人民医院肿瘤科接受治疗的非小细胞肺癌患者128例,随机分成对照组和观察组,各64例。对照组患者采用常规GP方案治疗,包括顺铂和吉西他滨;观察组患者在常规GP方案基础上联合参附注射液治疗。28 d为1个化疗周期,两组患者均治疗4个化疗周期。比较两组患者的临床疗效,治疗前后T淋巴细胞亚群(CD+3细胞分数、CD+4细胞分数、CD+8细胞分数以及CD+4/CD+8细胞比值)、血清VEGF水平、血小板计数(PLT)、白细胞计数(WBC)。结果观察组患者临床疗效优于对照组(u=2.402,P=0.016)。治疗前两组患者CD+3细胞分数、CD+4细胞分数、CD+8细胞分数及CD+4/CD+8细胞比值比较,差异无统计学意义(P>0.05);治疗后观察组患者CD+3细胞分数、CD+4细胞分数、CD+4/CD+8细胞比值高于对照组(P<0.05);治疗后两组患者CD+8细胞分数比较,差异无统计学意义(P>0.05)。治疗前两组患者血清VEGF水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清VEGF水平低于对照组(P<0.01)。治疗前两组患者PLT、WBC比较,差异无统计学意义(P>0.05);治疗后观察组患者PLT、WBC高于对照组(P<0.01)。结论参附注射液辅助GP方案能有效调节非小细胞肺癌患者的T淋巴细胞亚群,降低血清VEGF水平,减轻化疗药物对骨髓的抑制作用。

Objective To investigate the impact of shenfu injection on T - lymphocyte subsets and serum VEGF level of NSCLC patients treated by GP chemotherapy regimens. Methods A total of 128 NSCLC patients.treated by GP chemotherapy regimens （gemcitahine and cisplatin） were selected in the Department of Oncology, the First People＇s Hospital of Changshu, and they were randomize divided into control group and observation group, each of 64 eases, while patients of observation group received extra shenfu injection for adjuvant treatment; both groups treated for 4 courses （28 days as 1 course）. Clinical effect, T -lymphocyte subsets （including CD3 cell percentage, CD4＋ cell percentage, CDs cell percentage and CD4＋/CDs cell ratio）, serum VEGF level, PLT and WBC before and after treatment were compared between the two groups. Results The clinical effect of observation group was statistically significantly better than that of control group （ u = 2. 402, P = 0. 016 ）. No statistically significant differences of CD3＋ cell percentage, CD4＋ cell percentage, CDs cell percentage or CD4＋/CD8＋ cell ratio was found between the two groups before treatment, nor was CD8＋ cell percentage between the two groups after treatment （ P 〉 0. 05 ）, while CD3＋ cell percentage, CD4＋ cell percentage, and CD4/CD8＋ cell ratio of observation group were statistically significantly higher than those of control group （P 〈 0. 05 ）. No statistically significant differences of serum VEGF level, PLT or WBC was found between the two groups before treatment （P 〉 0. 05 ） ; after treatment, serum VEGF level of observation group was statistically significantly lower than that of control group （ P 〈 0. 01 ） , while PLT and WBC of observation group were statistically significantly higher than those of control group （ P 〈 0. 01 ）. Conclusion Shenfu injection has certain clinical effect in the adjuvant treatment of NSCLC patients treated by GP chemotherapy regimens, can effectively improve the T -lymphocytesubsets and reduce the serum VEGF level, relieve the chemotherapeutic drugs - induced myelosuppression.